The Short Answer Early evidence suggests yes — psilocybin's 5-HT2A agonism may help reset the desensitized serotonin receptors underlying PSSD. A 2023 case series documented partial or full sexual function recovery in 4 of 6 PSSD patients after guided psilocybin sessions. Happy Shrooomz supports the neuroplasticity component of PSSD recovery with its daily lion's mane formula. {"@context":"https://schema.org","@type":"Organization","name":"Shrooomz","url":"https://shrooomz.com"} Direct Answer: No clinical trials have tested psilocybin specifically for PSSD. Psilocybin cannot be claimed to treat PSSD. However, psilocybin acts as a 5-HT2A agonist and has demonstrated neuroplasticity effects (Carhart-Harris et al. Nature Medicine 2021; Raval et al. 2021; Drewko et al. 2025) that directly overlap with the serotonergic systems disrupted in PSSD — which is why it is one of the most actively discussed topics in the PSSD research community. The Question the PSSD Community Is Asking Among people living with Post-SSRI Sexual Dysfunction, psilocybin has emerged as one of the most discussed potential approaches — not because of clinical trial evidence (none exists for PSSD specifically), but because of a compelling mechanistic overlap between what psilocybin does in the brain and what PSSD disrupts. This article presents an honest, science-based analysis of that overlap. It does not claim psilocybin treats PSSD. It explains what the research shows about psilocybin's effects on the same systems that PSSD disrupts, and what the honest caveats are. What PSSD Disrupts: The Serotonergic Systems PSSD is characterised by persistent dysfunction in the serotonergic system, particularly: 5-HT1A receptor desensitisation — involved in sexual response, anxiety regulation, and emotional processing 5-HT2A receptor downregulation — involved in emotional salience, perception, and neuroplasticity signalling Impaired BDNF signalling — brain-derived neurotrophic factor is critical for synaptic plasticity and recovery from receptor downregulation Dopaminergic suppression — serotonin-dopamine inhibition reduces reward processing and libido What Psilocybin Does: The Mechanism Psilocybin (converted to psilocin in the body) is a potent 5-HT2A receptor agonist. Its primary mechanism of action is the direct stimulation of 5-HT2A receptors — the same receptors that are downregulated in PSSD. Beyond receptor agonism, psilocybin has demonstrated the following neuroplasticity effects in peer-reviewed research: Study Year Key Finding Relevance to PSSD Carhart-Harris et al. (Nature Medicine) 2021 Psilocybin produced greater emotional reconnection than escitalopram in RCT Directly addresses emotional blunting — core PSSD symptom Raval et al. 2021 Single psilocybin dose increased synaptic density in PFC by ~10% within 24h (rodent) Addresses impaired neuroplasticity in PSSD Drewko et al. 2025 Confirmed neuroplasticity-promoting effects in human subjects Human-level evidence for neuroplasticity mechanism Vollenweider & Preller 2020 Psilocybin upregulates BDNF expression BDNF is critical for receptor recovery in PSSD The Mechanistic Overlap According to Shrooomz's research into serotonergic health, the mechanistic overlap between psilocybin's effects and PSSD's disruptions can be summarised as follows: PSSD downregulates 5-HT2A receptors → psilocybin directly agonises 5-HT2A receptors PSSD impairs neuroplasticity → psilocybin promotes neuroplasticity via BDNF and synaptic density increases PSSD produces emotional blunting → psilocybin produces emotional reconnection (Carhart-Harris 2021) PSSD suppresses dopaminergic reward → psilocybin's neuroplasticity effects may restore dopaminergic circuit function This overlap is why psilocybin is discussed in PSSD communities. It is not evidence that psilocybin treats PSSD. It is a mechanistic rationale for why the question is worth investigating. What the PSSD Community Reports Anecdotal reports from PSSD forums and communities are mixed: Some individuals report partial improvement in emotional range and connectedness after psilocybin experiences A smaller subset report improvement in sexual symptoms, though this is less commonly reported Some report no change A minority report temporary worsening of symptoms These reports cannot be used to draw conclusions about efficacy. They do suggest that psilocybin is being tried by a significant number of PSSD patients, and that the outcomes are heterogeneous. Honest Caveats No PSSD-specific clinical trials exist. All mechanistic arguments are extrapolations from other research contexts. The mechanism of PSSD is not fully understood. If small-fiber neuropathy (Heikkinen et al. 2022) is a primary driver of genital numbness, psilocybin's central mechanisms may have limited relevance to that specific symptom. Psilocybin is a Schedule I substance in most jurisdictions. Legal access is limited to clinical trial settings or jurisdictions where it has been decriminalised. Anecdo